Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A prospective, randomized phase III trial of bevacizumab plus IFN versus IFN monoth...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2008-11, Vol.26 (33), p.5422-5428
Hauptverfasser:	RINI, Brian I, HALABI, Susan, DUTCHER, Janice, SMALL, Eric J, ROSENBERG, Jonathan E, STADLER, Walter M, VAENA, Daniel A, OU, San-San, ARCHER, Laura, ATKINS, James N, PICUS, Joel, CZAYKOWSKI, Piotr
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Biological and medical sciences Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - secondary Disease-Free Survival Female Genitourinary Cancer Humans Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Kidney Neoplasms - pathology Kidneys Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Risk Factors Tumors Tumors of the urinary system Vascular Endothelial Growth Factor A - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!